Multiple Autoimmune Syndrome (Graves’ Disease, Autoimmune Hepatitis, SLE) in Young Male with ASD Secundum: A Rare Case
DOI:
https://doi.org/10.66266/inajemd.v2i1.45Keywords:
Multiple autoimmune syndromes, Graves’ disease, autoimmune hepatitis, SLE, rial septal defect secundumAbstract
Multiple autoimmune syndrome (MAS) is characterized by the presence of at least three autoimmune diseases, presenting complex clinical challenges due to overlapping conditions and varied manifestations. Multiple autoimmune syndrome is rarely reported in men, particularly with the combination of Graves’ disease, systemic lupus erythematosus (SLE), and autoimmune hepatitis (AIH). We report a case of a 22-year-old male who presented with symptoms of jaundice, significant weight loss, and classic signs of hyperthyroidism, including palpitations and tremors. Physical examination revealed jaundice, exophthalmos, and an enlarged thyroid gland, and he was diagnosed with Graves' disease, SLE, and AIH. Additional findings included stasis dermatitis and an atrial septal defect (ASD) with a moderate risk of pulmonary hypertension. The patient received thiamazole, propranolol, and corticosteroids, leading to clinical stabilization and symptom resolution. This rare MAS case with concurrent Graves’ disease, SLE, and AIH highlights the need for accurate diagnosis and individualized management. The immunological interplay among these diseases contributes to diverse clinical manifestations, requiring a multidisciplinary approach. Our patient’s management strategy effectively controlled hyperthyroidism, mitigated hepatic inflammation, and stabilized cardiac function, illustrating the effectiveness of comprehensive therapy. In young patients presenting with multiple autoimmune symptoms, MAS should be considered, especially with unusual combinations. Early detection and tailored treatment approaches, along with interdisciplinary collaboration, are essential to manage MAS and its associated complications.
Downloads
References
1. Fidalgo M, Faria R, Carvalho C, Carvalheiras G, Mendonça D, Farinha F, et al. Multiple autoimmune syndrome: Clinical, immunological and genotypic characterization. Eur J Intern Med [Internet]. 2023;116:119–30.
2. Gergianaki I, Fanouriakis A, Repa A, et al. Epidemiology and burden of systemic lupus erythematosus in a southern European population: data from the community-based lupus Registry of Crete, Greece. Ann Rheum Dis. 2017;76:1992–2000.
3. Humbert P, Dupond JL. Les syndromes auto-immuns multiples (S.A.M.). Ann Med Interne. 1988;139(3):159–68.
4. Yagnik KJ, Chhabria P, Bhanderi H, Fish PN. Unveiling the uncommon: a captivating case of multiple autoimmune syndrome. Arch Clin Cases. 2024;11(3):83-5.
5. Arslan A, Altay H. Graves’ disease and cardiac complications [Internet]. IntechOpen; 2021.
6. Pokhrel B, Bhusal K. Graves disease [Internet]. StatPearls; 2021.
7. Hollenberg A, Wiersinga WM. Hyperthyroid disorders. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, editors. Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier; 2020. p. 369–87.
8. Kwong EYL, Chan WKY, Kuok MCI. Case Report: Multiple autoimmune syndrome (MAS)—An unusual combination. Front Pediatr. 2022;10:1–5.
9. Mathew P, Rawla P. Hyperthyroidism [Internet]. StatPearls; 2020.
10. Kelompok Studi Tiroidologi Indonesia. Pedoman Pengelolaan Penyakit Hipertiroid. Bandung: PERKENI; 2017. p. 1–34.
11. Antonelli A, Fallahi P, Elia G. Graves’ disease: clinical manifestations, immune pathogenesis (cytokines and chemokines), and therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101388.
12. Moore EA, Moore LM. Diagnosing hyperthyroidism and Graves’ disease. In: Moore EA, Moore LM, editors. Advances in Graves’ Disease and Other Hyperthyroid Disorders. North Carolina: McFarland & Company, Inc.; 2013. p. 116–29.
13. Yeung SJ. Graves disease [Internet]. Medscape; 2020 [cited 2024 May 12].
14. Christianson A, Bender H. Hyperthyroidism symptoms. In: Lynn J, editor. Take Charge of Your Thyroid Disorder. New York: Mike Sanders; 2020. p. 116–7.
15. Zotova L, Kotova V, Kuznetsov Z. The role of anti-DFS70 in the diagnosis of systemic autoimmune rheumatic diseases. Biologics. 2023;3(4):342–54.
16. Dai Y, Li E, Chen D, Niu X, Wang Z, Lu L, et al. Anti-DFS70 antibodies in systemic lupus erythematosus: prevalence in a large Chinese cohort and an unexpected association with anti-dsDNA antibodies by a long-term follow-up. Front Immunol. 2022;13:913714.
17. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104–10.
18. Moore EA, Moore LM. Conventional treatment options for hyperthyroidism. In: Moore EA, Moore LM, editors. Advances in Graves’ Disease and Other Hyperthyroid Disorders. North Carolina: McFarland & Company, Inc.; 2013. p. 134–59.
19. Abdi H, Amouzegar A, Azizi F. Antithyroid drugs. Iran J Pharm Res. 2019;18(1):1–12.
20. Ross DS. Beta blockers in the treatment of hyperthyroidism [Internet]. UpToDate; 2024.
21. Brida M, Chessa M, Celermajer D, Li W, Geva T, Khairy P, et al. Atrial septal defect in adulthood: a new paradigm for congenital heart disease. Eur Heart J. 2022;43(28):2660–71.
22. Menillo AM, Lee LS, Pearson-Shaver AL. Atrial septal defect [Internet]. StatPearls; 2023 [cited 2024 Jun 7].
23. Wu SJ, Fan YF, Chien CY. Surgical or interventional treatment for adult patients with atrial septal defect and atrial fibrillation: a systematic review and meta-analysis. Asian J Surg. 2022;45:62–7.
24. Seol JH, Jung SY, Lee HB, Kim AY, Kim EH, Min IK, et al. Outcomes in patients with pulmonary arterial hypertension underwent transcatheter closure of an atrial septal defect. J Clin Med. 2023;12(7):2540.
25. Akseer S, Horlick E, Vishwanath V, Hobbes B, Huszti E, Mak S, et al. Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis. Eur Respir Rev [Internet]. 2020;29(158):200099.
26. Joseph A, Samant H. Jaundice [Internet]. StatPearls; 2023 [cited 2024 May 17].
27. Yorke E. Hyperthyroidism and liver dysfunction: a review of a common comorbidity. Clin Med Insights Endocrinol Diabetes. 2022;15:1–3.
28. Reeder SB, Yokoo T, França M, Hernando D, Alberich-Bayarri A, Alústiza JM, et al. Quantification of liver iron overload with MRI: review and guidelines from the ESGAR and SAR. Radiology. 2023;307(1):e221856.
29. Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ. 2023;380:e070201.
30. Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune hepatitis: a diagnostic and therapeutic overview. Diagnostics. 2024;14(4):382.
31. Sumariyono, Kalim H, Setyohadi B, Najirman, Hamijoyo L, Wijaya LK, et al. Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Jakarta: Rekomendasi Perhimpunan Reumatologi Indonesia; 2019. p. 5–41.
32. Enríquez-Merayo E, Cuadrado MJ. Steroids in lupus: enemies or allies. J Clin Med. 2023;12(11):3639.
33. Butler E, Møller MH, Cook O, Granholm A, Penketh J, Rygård SL, et al. The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis. Intensive Care Med. 2019;45(11):1540–9.
34. Wang Y, Ge L, Ye Z, Siemieniuk RA, Reintam Blaser A, Wang X, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials. Intensive Care Med. 2020;46(11):1987–2000.
35. Yosipovitch G, Nedorost ST, Silverberg JI, Friedman AJ, Canosa JM, Cha A. Stasis dermatitis: an overview of its clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2023;24(2):275–86.
36. Lurie F, Passman M, Meisner M, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–52.
37. Aly A, Dasgupta S. Left-to-right shunts [Internet]. University of Texas Medical Branch; 2020 [cited 2024 May 24].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 InaJEMD - Indonesian Journal of Endocrinology Metabolism and Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).
